{"id":723,"date":"2020-12-22T06:45:39","date_gmt":"2020-12-22T06:45:39","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=723"},"modified":"2020-12-22T06:45:39","modified_gmt":"2020-12-22T06:45:39","slug":"19-dec-2020-sofosbuvir-daclatasvir-did-not-significantly-alleviate-symptoms-after-7-days-of-treatment-compared-with-control","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/19-dec-2020-sofosbuvir-daclatasvir-did-not-significantly-alleviate-symptoms-after-7-days-of-treatment-compared-with-control\/","title":{"rendered":"(19 Dec 2020) Sofosbuvir\/daclatasvir-did not significantly alleviate symptoms after 7 days of treatment compared with control"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1093\/jac\/dkaa501<\/p>\n<p class=\"\">IRCT20200403046926N1- Between 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir\/daclatasvir treatment arm (n = 27) or the control arm (n = 28). Baseline characteristics were similar across treatment arms. There was no significant difference in symptoms at Day 7. One patient was admitted to hospital in the sofosbuvir\/daclatasvir arm and four in the control arm, but the difference was not significant. After 1 month of follow-up, two patients reported fatigue in the sofosbuvir\/daclatasvir arm and 16 in the control arm; P &lt; 0.001.&nbsp; In this study, sofosbuvir\/daclatasvir did not significantly alleviate symptoms after 7 days of treatment compared with control. Although fewer hospitalizations were observed in the sofosbuvir\/daclatasvir arm, this was not statistically significant. Sofosbuvir\/daclatasvir significantly reduced the number of patients with fatigue and dyspnoea after 1 month. Larger, well-designed trials are warranted.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial https:\/\/doi.org\/10.1093\/jac\/dkaa501 IRCT20200403046926N1- Between 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir\/daclatasvir treatment arm (n = 27) or&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/19-dec-2020-sofosbuvir-daclatasvir-did-not-significantly-alleviate-symptoms-after-7-days-of-treatment-compared-with-control\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(19 Dec 2020) Sofosbuvir\/daclatasvir-did not significantly alleviate symptoms after 7 days of treatment compared with control&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,95],"tags":[96],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/723"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=723"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/723\/revisions"}],"predecessor-version":[{"id":725,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/723\/revisions\/725"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}